Division of Basic Medical Research FY2020 List of Projects - Research Program on Hepatitis
Program for Basic and Clinical Research on Hepatitis
First Year | Principal Investigator | Affiliation | Project Title | |
---|---|---|---|---|
FY2018 | HIASA Yoichi | Ehime University | Professor | Establishment of clinical immunotherapy against hepatitis B virus to stop the administration of nucleotide analogue |
FY2018 | MURATA Kazumoto | Jichi Medical University | Professor | Investigation for new therapeutic strategies and drug-discovery for withdrawal of drugs in HBV infection, based on novel cytokines’ production by nucleotide analogues |
FY2018 | MIZOKAMI Masashi | National Center for Global Health and Medicine | Project Leader | Development of cost-effective prevention protocols and elucidation of the mechanism for hepatitis B reactivation |
FY2018 | WATASHI Koichi | National Institute of Infectious Diseases | Senior Researcher | Nuclear hormone receptor ligands for controlling difficult-to-treat hepatitis C and steatohepatitis |
FY2018 | TAKEBE Takanori | Tokyo Medical and Dental University | Professor | Development of human NAFLD organoid panel for innovative drug screening |
FY2018 | UMEZAWA Akihiro | National Center for Child Health and Development | Director | Development of novel embryonic stem cell-based products for liver cirrhosis and liver failure |
FY2018 | INAGAKI Yutaka | Tokai University | Professor | Novel Diagnostic and Treatment Strategies for Regeneration of Fibrotic Liver by Focusing on an Exosome-carrying Regenerating Factor |
FY2018 | KOIKE Kazuhiko | The University of Tokyo | Professor | Study on the pathogenesis of metabolism-associated liver cancer including those associated with viral hepatitis |
FY2018 | KANTO Tatsuya | National Center for Global Health and Medicine | Director General | Development of tailored medicine for NASH patients with liver cancer based on lipidgenomics research |
FY2018 | NISHINA Hiroshi | Tokyo Medical and Dental University | Professor | Study of an innovative HBV-related liver disease therapy based on abnormal hepatocyte elimination |
FY2018 | TOITA Riki | National Institute of Advanced Industrial Science and Technology | Researcher | Development of inflammatory immune cell-targeted nanomedicine for the prevention and treatment of NASH/NAFLD |
FY2018 | YOSHIO Sachiyo | National Center for Global Health and Medicine | Chief | Development of novel therapy for the patients with cirrhosis based on immunological analysis targeting muscle-liver axis |
FY2018 | SHIRASAKI Takayoshi | Kanazawa University | Assistant Professor | Studies on a novel immune control mechanism against liver diseases |
FY2019 | ENOMOTO Nobuyuki | University of Yamanashi | Professor | Study on factors influencing post treatment pathological status in hepatitis C patients receiving direct acting antiviral agents using next generation sequencing technology |
FY2019 | TANAKA Yasuhito | Nagoya City University | Professor | Genome-wide research aimed at identifying host factors affecting the changes in disease conditions after direct acting antiviral therapies for hepatitis C |
FY2019 | KANEKO Shuichi | Kanazawa University | Professor | Study of preventing hepatocarcinogenesis from chronic hepatitis C |
FY2019 | KAWADA Norifumi | Osaka City University | Professor | Study on the development of regression therapy for liver fibrosis by using recombinant human Cytoglobin |
FY2019 | OHDAN Hideki | Hiroshima University | Professor | Research and development of immune-therapy using pluripotent stem cells as potential anti-hepatitis/hepatoma therapeutics |
FY2019 | KATO Naoya | Chiba University | Professor | Development of Hepatocarcinogenesis Prevention in Hepatitis C by Activating Innate Immune Response |
FY2019 | MURAMATSU Masamichi | National Institute of Infectious Diseases | Director | Basic research and development of novel diagnostic and therapeutic approaches for viral hepatitis |
FY2019 | OTSUKA Motoyuki | The University of Tokyo |
Lecturer |
Development of novel interventional methods against hepatitis B based on the comprehensive elucidation of its pathogenesis |
FY2019 | OKAMOTO Toru | Osaka University | Professor | Development of novel therapeutics for pathogenesis induced by hepatitis viruses |
FY2019 | TOKUNAGA Katsushi | National Center for Global Health and Medicine | Co-Director, Genome Medical Science Project | Study for clinical sequencing based on genome analysis of host and viral factors |
FY2019 | YAMAMOTO Takuya | National Institutes of Biomedical Innovation, Health and Nutrition | Project Leader | Establishment of therapeutic strategies toward a functional cure for HBV by innovative immunotherapies |
FY2019 | TAKEHARA Tetsuo | Osaka University | Professor | Study of outcome of liver cirrhotic patients received HCV elimination therapy |
FY2019 | NAKAGAWA Hayato | The University of Tokyo | Specially Appointed Lecturer | Relevance of burned-out phenomenon to the pathogenesis of NASH: Development of a new therapeutic strategy based on lipid metabolism |
FY2019 | ASAHINA Yasuhiro | Tokyo Medical and Dental University | Professor | Development of an innovative disease model using human iPS cell-derived liver organoids and creation of treatments to suppress hepatic fibrosis and hepatocarcinogenesis |
FY2019 | SUGIYAMA Masaya | National Center for Global Health and Medicine | Vice Director | Development of full-length HBV-POL expression system for drug discovery |
FY2019 | YAMANE Daisuke | Tokyo Metropolitan Institute of Medical Science | Chief Researcher | Study of Intrinsic Antiviral Signaling Pathways in Hepatocytes Toward the Development of Novel Antiviral Strategies |
FY2019 | TAKAYAMA Kazuo | Kyoto University | Junior Assistant Professor | Functional analysis and regulation of liver disease-associated gene TLL1 |
FY2020 | TAKEHARA Tetsuo | Osaka University | Professor | Elucidation of the progression of liver pathology such as liver carcinogenesis after hepatitis C virus elimination and its predictors |
FY2020 | CHAYAMA Kazuaki | Hiroshima University | Professor | Study of factors associated with health status and prognosis after successful HCV eradication |
FY2020 | AIZAKI Hideki | National Institute of Infectious Disease | Chief | Study on pathology and course of liver carcinogenesis after sustained virologic response in hepatitis C |
FY2020 | KUROSAKI Masayuki | Musashino Red Cross Hospital | Vice President | Study on the effect of resistance associated substitutions on clinical features of hepatitis C virus infection |
FY2020 | TAJIRI Hitoshi | Kindai University Nara Hospital | Researcher | Studies on evaluation of progression of viral hepatitis during childhood and on development of treatment strategy |
FY2020 | YATSUHASHI Hiroshi | National Hospital Organization Nagasaki Medical Center | Vice President | Study of contributing to improvement of QOL and improvement of prognosis in patients with liver cirrhosis |
FY2020 | TERAI Shuji | Niigata University | Professor | Translational research aiming for development of next generation exosome therapy for cirrhosis |
FY2020 | OSAFUNE Kenji | Kyoto University | Professor | Development of cell therapy against liver cirrhosis using human iPS cells and nonhuman primate liver disease models |
FY2020 | SAKAMOTO Naoya | Hokkaido University | Professor | Screening of prognostic biomarker by comprehensive serum and liver tissue glycomics |
FY2020 | HONDA Masao | Kanazawa University | Professor | Revealing the association of impaired barrier function of liver sinusoidal endothelial cells and the onset of lifestyle disease related non-B, non-C hepatitis and hepatocellular carcinoma |
FY2020 | KODAMA Takahiro | Osaka university | Assistant professor | Study of molecular mechanisms of NASH and non-B non-C liver cancer and exploration of their therapeutic targets |
FY2020 | KANDA Tatsuo | Nihon University School of Medicine | Associate Professor | Research and development of infection prevention, pathological mechanism, diagnosis and treatment for hepatitis A and E viruses |
FY2020 | UENO Hideki | Kyoto University | Professor | Promoting HBs seroconversion in chronic HBV infection |
FY2020 | NAKAMOTO Yasunari | University of Fukui | Professor | Development of Novel Targeted Immunotherapy for Chronic Hepatitis B to Regulate both Virus and Carcinogenesis |
FY2020 | NISHIDA Nao | National Center for Global Health and Medicine | Senior Researcher | Predictive Model to Prevent Development of Liver Disease Based on the Polygenic Risk Score (PRS) |
FY2020 | MIYOSHI Eiji | Osaka University Graduate School of Medicine | Professor | Study of novel hepatocarcinogenesis mechanism using glycotechnology and its application |
FY2020 | SEKIBA Kazuma | The University of Tokyo | Staff Doctor | Comprehensive identification of host factors maintaining HBV cccDNA by CRISPR technology for the development of new therapeutic methods |
FY2020 | MURAI Kazuhisa | Kanazawa University | Assistant Professor | Establishment of the research infrastructure for liver cancer microenvironment and exploratory research of a novel cancer immunotherapeutic target |
FY2020 | ABE Yuichi | Aichi Cancer Center Research Institute | Senior Scientist | Screening of novel diagnostic markers and therapeutic targets for NASH-derived hepatocellular carcinoma by ultra-sensitive multi-omics |
Program on the Innovative Development and the Application of New Drugs for Hepatitis B
First Year | Principal Investigator | Affiliation | Project Title | |
---|---|---|---|---|
FY2017 | TANAKA Yasuhito | Nagoya City University | Professor | Drug screening for developing HBV therapeutics and optimization of the hit compounds |
FY2017 | MORIYA Kyoji | The University of Tokyo | Professor | Search for drug candidates with novel mechanisms capable of efficient inhibition of hepatitis B virus propagation |
FY2017 | MURAMATSU Masamichi | National Institute for Infectious Diseases | Director | Basic research on hepatitis B virus life cycle and anti-viral development |
FY2017 | KATSUJI Kunio | Kobe University | Professor | Analysis of HBV life cycle by using sophisticated reporter HBV systems and its application to the development of a new strategy to suppress HBV infection and replication |
FY2017 | UEDA Keiji | Osaka University | Professor | Exploitation of anti-HBV strategies by targeting cellular factors functioning in the HBV life cycle |
FY2017 | KANTO Tatsuya | National Center for Global Health and Medicine | Director General | Establishment of novel therapeutic strategies against HBV - An integrated Immuno-omics approach |
FY2017 | FUJITA Takashi | Kyoto University | Visiting Professor | Research for HBV therapy development based on the establishment of HBV-sensitive cell and animal models |
FY2017 | TAKEHARA Tetsuo | Osaka University | Professor | Development of molecular pathogenesis and drug discovery using HBV infection models |
FY2017 | CHAYAMA Kazuaki | Hiroshima University | Professor | Hepatitis B virus eradication therapy development using a highly efficient cell culture system and a long term active chronic hepatitis B mouse model |
FY2017 | KANEKO Shuichi | Kanazawa University | Professor | Development of new antiviral therapies for hepatitis B virus |
FY2017 | MIZOKAMI Masashi | National Center for Global Health and Medicine | Project Leader | Comprehensive development of innovative therapeutic methods for complete inactivation of the HBV genome in the liver through application of genome-editing technology in personalized medicine |
FY2017 | MATSUURA Tomokazu | RIKEN | Visiting Senior Researcher | Drug discovery researches for licensing-out the next generation anti-HBV drugs |
FY2017 | MITSUYA Hiroaki | Kumamoto University | Distinguished Guest Professor | Development of novel anti-hepatitis B virus (HBV) agents potent against wild-type- and drug-resistant-HBVs |
FY2017 | WATASHI Koichi | National Institute of Infectious Diseases | Senior Researcher | Drug development against hepatitis B virus using chemical biological approaches and mathematical models |
FY2017 | ITO Kiyoaki | Aichi Medical University | Professor | Regulation of hepatitis B virus targeting by the control mechanisms of bile acid metabolism |
Last updated 05/25/21